Applications of (S)-N-Boc-Styrylalanine in Industrial Manufacturing

As a manufacturer specializing in enantiomerically pure amino acid derivatives, we supply (S)-N-Boc-Styrylalanine for several advanced industrial sectors. Our focus lies in supporting actual, high-value downstream industries where this chiral building block brings unique functionality and compliance to critical synthesis and formulation processes.

1. Peptide Active Pharmaceutical Ingredient (API) Synthesis

Pharmaceutical companies adopt (S)-N-Boc-Styrylalanine as a protected amino acid building block to introduce chiral styryl functionality into custom peptide APIs. In this scenario, the compound enters multi-step solid-phase or solution-phase peptide assembly, providing regioselective coupling and side-chain diversity that influences both biological activity and solubility properties of peptide drugs. Downstream, it supports the synthesis of investigational and commercial oligopeptides subject to rigorous regulatory requirements, including oncology, anti-infective, or hormonal therapies.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• EU GMP Annex 15 (Qualification and Validation)
• USP-NF General Chapters for Peptide Synthesis
• US FDA 21 CFR Part 211 (Finished Pharmaceuticals)

Typical usage ratio

• 2–10 mol% as a sequence-defined amino acid; precise ratio tuned by peptide design and pharmacophore requirements

Downstream process integration

• Introduction during protected amino acid condensation steps in SPPS (Fmoc/t-Boc techniques) or solution-phase peptide elongation

Final product types

• Synthetic peptide APIs (e.g., regulatory-submitted drug substances)
• Investigational New Drug (IND) candidate oligopeptides
• Custom therapeutic peptide intermediates for later deprotection and purification

2. Chiral Ligand Synthesis for Asymmetric Catalysis

Chemical manufacturers employ (S)-N-Boc-Styrylalanine to construct tailored ligands and organocatalysts, harnessing its stereochemistry and styryl group to impart enantioselectivity in downstream catalytic systems. The raw material is introduced at an intermediate stage, where it undergoes further modification to form chelating moieties or attached anchoring points essential for high-fidelity chiral transformations in specialty, agrochemical, and pharmaceutical manufacturing.

Industry compliance standards

• ISO 9001:2015 Quality Management
• REACH Regulation (EC) No 1907/2006
• European Pharmacopoeia 10.0 (where relevant for pharmaceutical catalysts)

Typical usage ratio

• 10–30 mol% relative to total ligand backbone or 5–25 wt% in the catalyst precursor batch; adjusted per desired chiral induction effect

Downstream process integration

• Coupling as a central scaffold in multi-step organic synthesis to generate bidentate or monodentate chiral ligands; subsequent incorporation into metal catalyst complexes

Final product types

• Chiral phosphine or amine ligands for homogeneous catalysis
• Custom organocatalyst modules for C–C, C–N stereoselective bond formation
• Metal–ligand complexes for pharmaceutical, fine chemical, or agro process reactions

3. Pharmaceutical Intermediate for Small Molecule Synthesis

Advanced pharmaceutical synthesis operations use (S)-N-Boc-Styrylalanine as a strategic intermediate to introduce both chiral and styrenyl fragments into non-peptidic drug scaffolds. Its protected amino acid form allows for selective deprotection, further functionalization, and incorporation into heterocyclic or aromatic systems without racemization. Such use is prevalent in the early and late stages of Active Pharmaceutical Ingredient (API) synthesis pipelines, especially where regulatory traceability and clean conversion to pharmacologically active materials are mandatory.

Industry compliance standards

• WHO Good Manufacturing Practices for Pharmaceutical Excipients
• US FDA ICH Q11 (API Development and Manufacture)
• Sanitary Standards SN/T 3377 (China) for Import/Export Pharmaceutical Intermediates

Typical usage ratio

• 0.5–5 mol% of total reactant input; batch size and ratio selected based on synthetic yield and structural requirements

Downstream process integration

• Used in amide or ester bond formation; deprotected and derivatized during convergent synthesis of drug intermediates and core molecules

Final product types

• Advanced pharmaceutical intermediates for regulatory submission dossiers
• New Molecular Entity (NME) lead structures featuring styryl and chiral motifs
• Custom small molecule drug substances with defined stereochemistry

4. Research-Grade Peptide Probe and Diagnostic Agent Development

Research reagent producers and life science laboratories apply (S)-N-Boc-Styrylalanine in the synthesis of peptide-based probes, conjugates, and diagnostic agents. Its ability to introduce unique aromatic character and chirality provides precise recognition elements for biochemical assays, molecular imaging, or binding studies. Manufacturers incorporate this raw material into proprietary peptide sequences that serve as standards or functionalized markers in high-sensitivity diagnostic kits and analytical methods.

Industry compliance standards

• ISO 13485:2016 for medical device quality management systems (diagnostic reagents)
• CE Marking Directive 98/79/EC for in vitro diagnostic medical devices
• US FDA 21 CFR Part 820 (Quality System Regulation)

Typical usage ratio

• 1–6 mol% within labeled or functional peptide segments; adjusted by labeling density and assay sensitivity requirements

Downstream process integration

• Inserted during automated peptide synthesis cycles for later conjugation or biotinylation in research and diagnostic workflows

Final product types

• Peptide-based molecular probes for imaging or labelling
• Biotinylated or fluorescent-labeled peptide controls for diagnostics
• Reference standards and calibrators for research assays